Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Completed 5Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Supratentorial Brain Tumor Surgery 1Post-operative Residual Curarization 1

Interventions

Cisplatin 517Radiotherapy 378Cyclophosphamide 368Carboplatin 359Capecitabine 342Paclitaxel 337Oxaliplatin 336Gemcitabine 322Docetaxel 317Fluorouracil 290Drug Therapy 276Bevacizumab 248apatinib 247camrelizumab 219Etoposide 201Irinotecan 182Doxorubicin 181Leucovorin 163Dexamethasone 161pembrolizumab 153Neoadjuvant Therapy 146sintilimab 145anlotinib 140Blood Specimen Collection 140Pemetrexed 138Cytarabine 138toripalimab 133Surgical Procedures, Operative 131Radiosurgery 131S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Neostigmine × Clear all
NCT03996655 2019-06-25

Different Reversal Agents in Pediatric Day-case Cancer Surgery

National Cancer Institute, Egypt

Phase 4 Unknown
80 enrolled

Post-operative Residual Curarization

NCT02944175 2018-10-19

Cerebral Oxygenation and Metabolism After Reversal Of Rocuronium: Comparison Between Sugammadex Versus Neostigmine

Mansoura University

Phase NA Unknown
40 enrolled

Supratentorial Brain Tumor Surgery

Data powered by HemOnc (CC BY 4.0) Colophon âš¡